ABSTRACT
Introduction: Concurrent chemo-radiation is the standard ofcare for locally advanced head and neck carcinoma. Duringlater part of radiation treatment schedule, there is acceleratedrepopulation of surviving tumour cells. So the treatment shouldbe completed as early as possible. Study aimed to comparethe loco-regional control rates between the acceleratedfractionated and conventional fractionated radiotherapy andto compare the rate of acute and late toxicities between thetwo arms.Material and Methods: Thirty patients with locally advancedhead and neck cancer in the study arm (ARM-A) received sixfractions of radiotherapy per week and thirty-two patients in thecontrol arm (ARM-B) received five fractions of radiotherapyper week. Total radiation dose was same in both arms. Inj.Cisplatin at a dose of 100mg/m2 was given to the patients ofboth the arms every three weeks as a radiosensitizer agent.Results: Complete response rate (19/30 vs 14/32) rate thoughhigher in the study arm, was not statistically significant.Similarly overall response rate (25/30 vs 21/32) was notstatistically significant (P value – 0.15). Among acutetoxicities only dysphagia was significantly higher in the studyarm (P value-0.024). Late toxicities were similar in both thearms.Conclusion: So accelerated fractionation radiotherapy canbe used for treating locally advanced head and neck cancerpatients to improve loco-regional control rate with acceptabletoxicities.
ABSTRACT
AIM: The aim of this study is to assess the efficacy and toxicity of 5‑flurouracil (5‑FU) and cisplatin (PF) versus taxane and cisplatin (TP) as induction chemotherapy in locally advanced head and neck squamous cell cancer. MATERIALS AND METHODS: There were 50 patients in each arm, matched for age, performance state, site and stage of disease. PF arm (cisplatin ‑ 100 mg/m2 D1, 5‑FU ‑ 1000 mg/m2 D1‑D5) TP arm (docetaxel ‑ 75 mg/m2 or paclitaxel ‑ 175 mg/m2 on D1, cisplatin 75 mg/m2 on D2), received once in 3 weeks for 3 cycles. Patients without progressive disease underwent either surgery or chemoradiation. The primary end point was overall response rate (ORR) and secondary endpoint was toxicity. RESULTS: In a total of 100 patients in our study, 44 in PF and 47 in TP arm were evaluable. ORR was 86.6% in PF arm and 82.9% in TP arm (P = 0.71).There were more Grade 3 or 4 events of neutropenia, mucositis (P ≤ 0.05) and myelosuppression diarrhea, febrile neutropenia (P ≥ 0.05) in PF arm compared with TP arm. Post‑chemotherapy hospital admissions due to toxicity were more frequent in PF arm (38.6% vs. 19%), dropout rate due to toxicity (9% vs. 0%) and deaths (6.8% vs. 2.1%) were more common in PF arm compared with TP arm. CONCLUSION: TP induction chemotherapy better tolerated than PF, which has similar efficacy, further multicenter randomized controlled studies; involving a large sample size is needed to confirm our data.
ABSTRACT
PURPOSE: The aim of the present study was to retrospectively evaluate the incidence of hypothyroidism in locally advanced head and neck cancer patients who received radiotherapy (RT) either with or without neck dissection. MATERIALS AND METHODS: From January 2000 to December 2005, 115 patients with locally advanced head and neck cancer and who received definitive RT or postoperative RT including standard anterior low-neck field were recruited to be part of this study. Nineteen patients had undergone ipsilateral neck dissection, whereas, 18 patients underwent bilateral neck dissection, and 78 patients were received RT alone. Patients' ages ranged from 28 to 85 years (median, 59 years) and there were a total of 73 male and 42 female patients. The primary tumor sites were the oral cavity, oropharynx, hypopharynx, larynx, and other sites in 18, 40, 28, 22 and 7 patients, respectively. Radiation dose to the thyroid gland ranged from 44 Gy to 66 Gy with a median dose of 50 Gy. Follow-up time ranged from 2 to 91 months, with a median of 29 months. RESULTS: The 1- and 3-year incidence of hypothyroidism was 28.7% (33 patients) and 33.0% (38 patients), respectively. The median time to detection of hypothyroidism was 8.5 months (range, 0 to 36 months). A univariate analysis revealed that neck node dissection was a risk factor for hypothyroidism (p=0.037). However, no factor was statistically significant from the results of a multivariate analysis. CONCLUSION: Patients treated for advanced head and neck cancer with radiotherapy with or without neck dissection will develop hypothyroidism. It is important to check the thyroid function periodically in these patientsespecially with the risk factor of neck node dissection.